Department of Cosmetic Raw Materials Chemistry, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.
Eur J Med Chem. 2010 Jun;45(6):2613-21. doi: 10.1016/j.ejmech.2010.02.050. Epub 2010 Mar 1.
Here we present the synthesis of the new chelating ligands 1-benzothiazol-2-yl-5-(2-hydroxyphenyl)-3-methyl-1H-pyrazole-4-carboxylic acid methyl ester (2a) and 1-(6-chloropyridazin-3-yl)-5-(2-hydroxyphenyl)-3-methyl-1H-pyrazole-4-carboxylic acid methyl ester (2b), obtained in the reaction of 2-methyl-4-oxo-4H-chromene-3-carboxylic acid methyl ester (1) with hydrazine derivatives. These ligands 2a and 2b create solid complexes with Pt(II) (4a, 4b), Pd(II) (5a, 5b) and Cu(II) (6a, 7a, 8a, 8b and 9b) metal ions or can be cyclized to 1-benzothiazol-2-yl-3-methyl-1H-chromeno[4,3-c]pyrazol-4-one (3a) or 1-(6-chloropyridazin-3-yl)-3-methyl-1H-chromeno[4,3-c]pyrazol-4-one (3b). The crystal and molecular structures of ligand 2a, its Cu(II) complexes 6a and 7a were determined by X-ray diffraction method. Cytotoxic activity of the ligands 2a and 2b and their complexes 4a, 4b, 5a, 5a, 6a, 8a, 8b and 9b, and modulation of expression of BAX and P53 genes are also shown.
在这里,我们展示了新螯合剂 1-苯并噻唑-2-基-5-(2-羟基苯基)-3-甲基-1H-吡唑-4-羧酸甲酯(2a)和 1-(6-氯哒嗪-3-基)-5-(2-羟基苯基)-3-甲基-1H-吡唑-4-羧酸甲酯(2b)的合成,这两种配体是由 2-甲基-4-氧代-4H-色烯-3-羧酸甲酯(1)与肼衍生物反应得到的。这些配体 2a 和 2b 与 Pt(II)(4a、4b)、Pd(II)(5a、5b)和 Cu(II)(6a、7a、8a、8b 和 9b)金属离子形成固体配合物,或者可以环化生成 1-苯并噻唑-2-基-3-甲基-1H-色烯[4,3-c]吡唑-4-酮(3a)或 1-(6-氯哒嗪-3-基)-3-甲基-1H-色烯[4,3-c]吡唑-4-酮(3b)。配体 2a、其 Cu(II)配合物 6a 和 7a 的晶体和分子结构通过 X 射线衍射法确定。还展示了配体 2a 和 2b 及其配合物 4a、4b、5a、5a、6a、8a、8b 和 9b 的细胞毒性活性以及 BAX 和 P53 基因表达的调节。